MAINRITSyS: Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease (clinicaltrials.gov) - Sep 19, 2026 - P2 | N=120 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris
New P2 trial • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • MUC1 • SFTPD
|